<SEC-DOCUMENT>0001808805-22-000101.txt : 20220928
<SEC-HEADER>0001808805-22-000101.hdr.sgml : 20220928
<ACCEPTANCE-DATETIME>20220928160157
ACCESSION NUMBER:		0001808805-22-000101
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20220926
FILED AS OF DATE:		20220928
DATE AS OF CHANGE:		20220928

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Sankar Subramanian
		CENTRAL INDEX KEY:			0001856744

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39434
		FILM NUMBER:		221275986

	MAIL ADDRESS:	
		STREET 1:		C/O NAUTILUS BIOTECHNOLOGY, INC.
		STREET 2:		201 INDUSTRIAL RD. #310
		CITY:			SAN CARLOS
		STATE:			CA
		ZIP:			94070

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Nautilus Biotechnology, Inc.
		CENTRAL INDEX KEY:			0001808805
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		2701 EASTLAKE AVE EAST
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98102
		BUSINESS PHONE:		206-333-2001

	MAIL ADDRESS:	
		STREET 1:		2701 EASTLAKE AVE EAST
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98102

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ARYA Sciences Acquisition Corp III
		DATE OF NAME CHANGE:	20200408
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>wf-form4_166439528878324.xml
<DESCRIPTION>FORM 4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0306</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2022-09-26</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001808805</issuerCik>
        <issuerName>Nautilus Biotechnology, Inc.</issuerName>
        <issuerTradingSymbol>NAUT</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001856744</rptOwnerCik>
            <rptOwnerName>Sankar Subramanian</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O NAUTILUS BIOTECHNOLOGY, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>2701 EASTLAKE AVENUE EAST</rptOwnerStreet2>
            <rptOwnerCity>SEATTLE</rptOwnerCity>
            <rptOwnerState>WA</rptOwnerState>
            <rptOwnerZipCode>98102</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>Senior VP, Product Development</officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2022-09-26</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>P</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>10000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>2.025</value>
                    <footnoteId id="F1"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>86250</value>
                    <footnoteId id="F2"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2022-09-27</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>P</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>5000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>2.0298</value>
                    <footnoteId id="F3"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>91250</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <derivativeTable></derivativeTable>

    <footnotes>
        <footnote id="F1">Represents the weighted average share price of an aggregate total of 10,000 shares purchased in the price range of $2.00 to $2.05 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.</footnote>
        <footnote id="F2">Includes 1,250 shares of Common Stock acquired on June 1, 2022 through the Issuer's 2021 Employee Stock Purchase Plan.</footnote>
        <footnote id="F3">Represents the weighted average share price of an aggregate total of 5,000 shares purchased in the price range of $2.02 to $2.04 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.</footnote>
    </footnotes>

    <remarks></remarks>

    <ownerSignature>
        <signatureName>/s/ Matthew B. Murphy, as Attorney-in-Fact</signatureName>
        <signatureDate>2022-09-27</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
